Clinical endpoint | Everolimus and exemestane group (N = 482) | Placebo and exemestane group (N = 238) | Alpelisib and fulvestrant group (N = 169) | Placebo and fulvestrant group (N = 172) |
---|---|---|---|---|
Best overall response (%) | ||||
Complete response CR | 0 | 0 | 0.6 | 1.2 |
Partial response PR | 12.6 | 2.1 | 26.0 | 11.6 |
Stable disease SD | 73.4 | 62.8 | 34.3 | 36.6 |
Neither complete response nor progressive diseasea | / | / | 22.5 | 14.5 |
Progressive disease PD | 5.8 | 23.4 | 9.5 | 30.8 |
Unknown | 8.2 | 11.7 | 7.1 | 5.2 |
Overall response (%) | 12.6 | 2.1 | 26.6 | 12.8 |
Clinical benefit (%) | 49.9 | 22.2 | 61.5 | 45.3 |